Back to Search Start Over

Dual Piperidine-Based Histamine H 3 and Sigma-1 Receptor Ligands in the Treatment of Nociceptive and Neuropathic Pain.

Authors :
Szczepańska K
Karcz T
Dichiara M
Mogilski S
Kalinowska-Tłuścik J
Pilarski B
Leniak A
Pietruś W
Podlewska S
Popiołek-Barczyk K
Humphrys LJ
Ruiz-Cantero MC
Reiner-Link D
Leitzbach L
Łażewska D
Pockes S
Górka M
Zmysłowski A
Calmels T
Cobos EJ
Marrazzo A
Stark H
Bojarski AJ
Amata E
Kieć-Kononowicz K
Source :
Journal of medicinal chemistry [J Med Chem] 2023 Jul 27; Vol. 66 (14), pp. 9658-9683. Date of Electronic Publication: 2023 Jul 07.
Publication Year :
2023

Abstract

In search of new dual-acting histamine H <subscript>3</subscript> /sigma-1 receptor ligands, we designed a series of compounds structurally based on highly active in vivo ligands previously studied and described by our team. However, we kept in mind that within the previous series, a pair of closely related compounds, KSK67 and KSK68 , differing only in the piperazine/piperidine moiety in the structural core showed a significantly different affinity at sigma-1 receptors (σ <subscript>1</subscript> Rs). Therefore, we first focused on an in-depth analysis of the protonation states of piperazine and piperidine derivatives in the studied compounds. In a series of 16 new ligands, mainly based on the piperidine core, we selected three lead structures ( 3 , 7 , and 12 ) for further biological evaluation. Compound 12 showed a broad spectrum of analgesic activity in both nociceptive and neuropathic pain models based on the novel molecular mechanism.

Details

Language :
English
ISSN :
1520-4804
Volume :
66
Issue :
14
Database :
MEDLINE
Journal :
Journal of medicinal chemistry
Publication Type :
Academic Journal
Accession number :
37418295
Full Text :
https://doi.org/10.1021/acs.jmedchem.3c00430